Physician profile
Mark T Knower
NPI 1124077268
$583.14
in general payments reported to CMS, 2019-2025
14 companies · $47.87 in 2025
The $47.87 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $117 · 2021: $354 · 2022: $14.17 · 2023: $50.06 · 2025: $47.87.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $97.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $97.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $118.76 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $86.89 | 2021 | |
| United Therapeutics Corporation | $64.03 | 2021 | |
| Mylan Specialty L.P. | $44.60 | 2020-2021 | |
| Apria Healthcare LLC | $43.77 | 2021 | |
| Edwards Lifesciences Corporation | $34.61 | 2023 | Hemosphere |
| Glaxosmithkline, LLC. | $29.75 | 2021 | |
| Chiesi USA, INC. | $29.62 | 2022-2023 | Kengreal, Cleviprex |
| Regeneron Healthcare Solutions, INC. | $25.56 | 2021 | |
| La Jolla Pharmaceutical Company | $24.58 | 2025 | Giapreza |
| Abiomed | $23.29 | 2025 | |
| Philips North America LLC | $21.29 | 2021 | |
| Genzyme Corporation | $19.63 | 2020 | |
| Janssen Pharmaceuticals, INC | $16.76 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Knower listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.